Peptide Producers Bet Big on Therapeutic Growth

CPC Scientific and AmbioPharm advance 2022 to 2023 expansions as CPCs Rocklin site targets 2026 operations

19 Nov 2025

Several US peptide contract manufacturers are moving ahead with expansion plans first announced in 2022 and 2023, as they seek to add production capacity for a growing pipeline of peptide-based therapeutics.

CPC Scientific said in June 2022 that it would build a 41,000 sq ft good manufacturing practice facility in Rocklin, California. Company materials now indicate the site is expected to be fully operational by 2026. The project is designed to broaden domestic access to clinical and commercial peptide production, although CPC has not released confirmed output estimates for the plant. The group says its global network can support more than 1,000kg of peptide active ingredient production a year, with typical batch sizes of 20–25kg.

AmbioPharm announced on May 17 2023 that it had upgraded its headquarters in North Augusta, South Carolina, adding microwave peptide synthesizers and expanding its GMP suites. The company said the improvements allow annual capacity of up to one metric ton across its facilities, a figure it described as potential capability rather than verified operating output.

While these initiatives do not signal a broad industry build-out, they illustrate how selected CDMOs are investing in equipment and facilities to meet rising demand for complex peptide drugs. Both groups aim to offer greater flexibility for clinical and commercial programmes and to provide more resilient supply for biopharmaceutical clients.

As projects launched in 2022 and 2023 continue, CPC Scientific and AmbioPharm show how US peptide manufacturers are positioning themselves for sustained growth in the peptide therapeutics market.